AttendMe Owl Logo
AttendMe
Evidence Evolution
EndocrinologyEndocrinology

How This Evidence Evolved

GLP-1 Receptor Agonists Beyond Glycemia

From glucose-lowering to cardiovascular, renal, and metabolic protection

7.1

Timeline

Trial
Guideline
Approval
Meta-analysis
Signal

Early observations and pilot data that first suggested a new direction

LEADER tested cardiovascular outcomes when liraglutide was added to standard care in type 2 diabetes. Among 9,340 patients at high cardiovascular risk, the first cardiovascular death, nonfatal MI or nonfatal stroke occurred in 13.0% with liraglutide versus 14.9% with placebo over a median 3.8 years (HR 0.87, 95% CI 0.78–0.97). This demonstrated a cardiovascular outcome benefit in the tested population, extending the clinical question beyond glucose levels alone.
Proof

Landmark RCTs and pivotal trials that established the evidence base

SUSTAIN-6 randomized 3,297 patients with type 2 diabetes to once-weekly semaglutide or placebo for 104 weeks. Cardiovascular death, nonfatal MI or nonfatal stroke occurred in 6.6% versus 8.9% (HR 0.74, 95% CI 0.58–0.95). STEP 1 studied 1,961 adults with overweight or obesity without diabetes: semaglutide 2.4 mg plus lifestyle intervention produced a mean 14.9% weight reduction at 68 weeks versus 2.4% with placebo. These trials address distinct cardiovascular and weight outcomes.
Extension

Follow-up studies, subgroup analyses, and real-world validation

SELECT enrolled 17,604 patients with established cardiovascular disease and overweight or obesity but no diabetes. At a mean follow-up of 39.8 months, the primary cardiovascular endpoint occurred in 6.5% with semaglutide versus 8.0% with placebo (HR 0.80; 95% CI 0.72–0.90). FLOW enrolled 3,533 patients with type 2 diabetes and chronic kidney disease. Major kidney disease events were 24% lower with semaglutide than placebo. FLOW reported early cessation at a prespecified interim analysis; that statement should not be extended to SELECT.
Guidelines

Integration into clinical practice guidelines and recommendations

ADA/EASD 2022 applies to non-pregnant adults with T2D. Use proven-benefit GLP-1 RA for MACE reduction in established CVD; consider it with multiple CV risk factors. Decisions are independent of HbA1c/metformin. Use SGLT2i for HF; in CKD, initiate proven-benefit SGLT2i if eGFR ≥20 mL/min/1.73 m² and UACR >30 mg/g (regional indications vary). If not tolerated or contraindicated in CKD, consider GLP-1 RA with proven CV benefit to reduce MACE.
ADA/EASD

In T2D, consider GLP-1 RA before insulin if no contraindications; use proven-benefit GLP-1 RA to reduce MACE in established CVD.

ADA/EASD consensus

Consider GLP-1 RA before insulin in T2D when no contraindications; they are contraindicated with personal/family medullary thyroid cancer or MEN2. Do not delay indicated insulin. Insulin may be preferred for severe hyperglycemia (HbA1c >10%), especially with weight loss/ketosis, acute glycemic dysregulation, underweight or suspected type 1 diabetes.

Now

Current standard of care and ongoing research directions

FLOW extends the evidence to clinically important kidney outcomes in type 2 diabetes with chronic kidney disease. Semaglutide reduced major kidney disease events, slowed the annual decline in eGFR and reduced cardiovascular and all-cause mortality in this population. The practical question is how to select patients and balance these benefits with treatment burden and tolerability.

Landmark Trials in This Story

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.

Related Evidence

Frequently Asked Questions

Do GLP-1 receptor agonists provide cardiovascular benefit in patients without diabetes?+
SELECT studied 17,604 patients with established cardiovascular disease and overweight or obesity without diabetes. Weekly semaglutide 2.4 mg reduced cardiovascular death, nonfatal MI or nonfatal stroke versus placebo (HR 0.80, 95% CI 0.72–0.90; P<.001).
What kidney benefits have been demonstrated with GLP-1 receptor agonists?+
FLOW found 24% lower major kidney disease event risk with semaglutide in type 2 diabetes and CKD (HR 0.76, 95% CI 0.66–0.88). Kidney-specific components had HR 0.79; cardiovascular death had HR 0.71. Early cessation was recommended at a prespecified interim analysis.
How much weight loss can be expected with semaglutide for obesity?+
In STEP 1, semaglutide 2.4 mg plus lifestyle intervention produced mean weight loss of 14.9% at 68 weeks versus 2.4% with placebo in adults with overweight or obesity without diabetes. At least 5% weight loss occurred in 86.4% with semaglutide.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical decisions should always be based on individual patient assessment, local guidelines, and professional judgement.

All data sourced from published, peer-reviewed articles and clinical practice guidelines.

Claims checked against cited sources: 10 November 2026